Cowen Reiterates Outperform on Ironwood Pharma (IRWD) Following IW-1973 Data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. AVGO
2. CDNS
3. META
4. SSD
5. SPY
6. AAPL
7. JBLU
8. ANT
9. PECO
10. BA

Go back to Cowen Reiterates Outperform on Ironwood Pharma (IRWD) Following IW-1973 Data

Ironwood Pharma (IRWD) Reports Positive Impact from Praliciguat Phase IIa Study Data on Metabolic a& Cardiovascular Clinical Endpoints

June 25, 2018 5:54 AM EDT

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today presented additional data from an exploratory Phase IIa study of praliciguat (IW-1973) in patients with type 2 diabetes and hypertension during an oral session at the American Diabetes Associations (ADA) 78th Scientific Sessions in Orlando, Fla. Praliciguat is an oral, once-daily soluble guanylate cyclase (sGC) stimulator that... More

Ironwood Pharma (IRWD) Commences Pivotal Phase III Program for IW-3718 in Persistent Gastroesophageal Reflux Disease

June 21, 2018 4:06 PM EDT

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the initiation of two Phase III clinical trials evaluating the safety and efficacy of IW-3718 in patients with persistent gastroesophageal reflux disease (GERD). Persistent GERD affects an estimated 10 million Americans who continue to suffer from heartburn and regurgitation despite receiving treatment with proton... More